Biased Agonism as an Emerging Strategy in the Search for Better Opioid Analgesics

被引:12
作者
Piekielna-Ciesielska, Justyna [1 ]
Wtorek, Karol [1 ]
Janecka, Anna [1 ]
机构
[1] Med Univ Lodz, Dept Biomol Chem, Mazowiecka 6-8, PL-92215 Lodz, Poland
关键词
Opioid receptors; opioid peptides; antinociceptive activity; biased agonism; bias factor; morphine; MU-AGONIST/DELTA-ANTAGONIST; ENDOMORPHIN ANALOGS; RECEPTOR AGONIST; FUNCTIONAL SELECTIVITY; TOLERANCE; LIGANDS; POTENT; PAIN; EXPRESSION; DISCOVERY;
D O I
10.2174/0929867326666190506103124
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Morphine and related drugs that act through activating opioid receptors are the most effective analgesics for the relief of severe pain. They have been used for decades, despite the range of unwanted side effects that they produce, as no alternative has been found so far. The major goal of opioid research is to understand the mechanism of action of opioid receptor agonists and to improve the therapeutic utility of opioid drugs. In the search for safer and more potent analgesics, analogs with mixed opioid receptor profile gained a lot of interest. However, recently the concept of biased agonism, that highlights the fact that some ligands are able to differentially activate receptor downstream pathways, became a new approach in the design of novel drug candidates for clinical application. In this review, we summarize current knowledge on the development of opioid ligands of peptide and non-peptide structure, showing how much opioid pharmacology evolved in recent years.
引用
收藏
页码:1562 / 1575
页数:14
相关论文
共 27 条
  • [21] The endomorphin-1/2 and dynorphin-B peptides display biased agonism at the mu opioid receptor
    Justin LaVigne
    Attila Keresztes
    Daniel Chiem
    John M. Streicher
    Pharmacological Reports, 2020, 72 : 465 - 471
  • [22] The endomorphin-1/2 and dynorphin-B peptides display biased agonism at the mu opioid receptor
    LaVigne, Justin
    Keresztes, Attila
    Chiem, Daniel
    Streicher, John M.
    PHARMACOLOGICAL REPORTS, 2020, 72 (02) : 465 - 471
  • [23] Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform
    Vasudevan, Lakshmi
    Vandeputte, Marthe
    Deventer, Marie
    Wouters, Elise
    Cannaert, Annelies
    Stove, Christophe P.
    BIOCHEMICAL PHARMACOLOGY, 2020, 177
  • [24] Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers
    Soergel, David G.
    Subach, Ruth Ann
    Burnham, Nancy
    Lark, Michael W.
    James, Ian E.
    Sadler, Brian M.
    Skobieranda, Franck
    Violin, Jonathan D.
    Webster, Lynn R.
    PAIN, 2014, 155 (09) : 1829 - 1835
  • [25] β-arrestin-2-biased agonism of delta opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) in primary sensory neurons
    Rowan, Matthew P.
    Szteyn, Kalina
    Doyle, Allison P.
    Gomez, Ruben
    Henry, Michael A.
    Jeske, Nathaniel A.
    MOLECULAR PAIN, 2014, 10
  • [26] Plasticity of Signaling by Spinal Estrogen Receptor α, κ-Opioid Receptor, and Metabotropic Glutamate Receptors over the Rat Reproductive Cycle Regulates Spinal Endomorphin 2 Antinociception: Relevance of Endogenous-Biased Agonism
    Liu, Nai-Jiang
    Murugaiyan, Vijaya
    Storman, Emiliya M.
    Schnell, Stephen A.
    Kumar, Arjun
    Wessendorf, Martin W.
    Gintzler, Alan R.
    JOURNAL OF NEUROSCIENCE, 2017, 37 (46) : 11181 - 11191
  • [27] Buprenorphine: Its Emerging Role as a Strategy to Reduce Full Opioid Agonist Use in the ICU
    Devlin, John W.
    CRITICAL CARE MEDICINE, 2023, 51 (12) : 1817 - 1819